J Rheum Dis.  2013 Dec;20(6):361-363. 10.4078/jrd.2013.20.6.361.

A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis

Affiliations
  • 1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • 2Department of Internal Medicine, Malgeunsem Hospital, Changwon, Korea.
  • 3Department of Internal Medicine, Young-do Hospital, Busan, Korea.
  • 4Department of Internal Medicine, Busan St. Mary's Medical Center, Busan, Korea.
  • 5Division of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital, Busan, Korea. drbaek@pusan.ac.kr
  • 6Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

Abstract

Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFalpha) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFalpha agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFalpha agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.

Keyword

Ankylosing spondylitis; End-stage renal disease; Peritoneal dialysis; Tumor necrosis factor-alpha

MeSH Terms

Adult
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Humans
Immunoglobulin G
Kidney Failure, Chronic
Male
Metabolism
Necrosis
Peritoneal Dialysis*
Pharmacokinetics
Receptors, Tumor Necrosis Factor
Renal Insufficiency
Spondylitis, Ankylosing*
Tumor Necrosis Factor-alpha
Etanercept
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha

Reference

References

1. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998; 17:524–30.
Article
2. van der Heijde D, Sieper J, Maksymowych WP, Douga-dos M, Burgos-Vargas R, Landewe R, et al. Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70:905–8.
Article
3. Lange U, Stapfer G, Ditting T, Geiger H, Teichmann J, Müller-Ladner U, et al. Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis. Eur J Med Res. 2007; 12:573–81.
4. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70:896–904.
Article
5. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13:629–38.
6. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005; 57:1407–13.
Article
7. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006; 45:357–9.
Article
8. Sugioka Y, Inui K, Koike T. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol. 2008; 18:293–5.
Article
9. Saougou I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin Rheumatol. 2010; 29:1455–9.
Article
10. Shimojima Y, Matsuda M, Ishii W, Ikeda S. Adalimumab monotherapy in a patient with psoriatic arthritis associated with chronic renal failure on hemodialysis: a case report and literature review. Clin Med Insights Case Rep. 2012; 5:13–7.
Article
11. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. 2012; 32:1785–7.
Article
Full Text Links
  • JRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr